Category - Developments

Vital Therapies

Vital Therapies updates Phase 3 trial

Vital Therapies (NASDAQ:VTL) updated its Phase 3 trial, VTL-308, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis. A total of 38 subjects have been enrolled at sites in the U.S. and...

IntelGenx Logo

IntelGenx, Chemo Group sign CNS accord

IntelGenx Technologies (OTCQX:IGXT; TSX-V:IGX) has signed a definitive agreement with Chemo Group for the co-development and commercialization of a generic tablet in the area of CNS on a worldwide basis. According to...

Titan Pharmaceuticals Logo

Braeburn files for $150-million IPO

Closely held Braeburn Pharmaceuticals filed with U.S. regulators to raise up to $150-million in an initial public offering, seven months after its Probuphine implant to treat opioid addiction was approved by the FDA...

IntelGenx Logo

IntelGenx in development pact with Endo

IntelGenx (OTCQX:IGXT; TSX-V:IGX) entered into a co-development and commercialization agreement with Endo Ventures for a new product utilizing IntelGenx’ proprietary VersaFilm for the USA market. Under the accord...

Dipexium Pharmaceuticals

Dipexium, PLx Pharma agree to merge

Dipexium Pharmaceuticals (NASDAQ:DPRX) and closely held PLx Pharma have agreed to merge in an all-stock transaction.  Following closing, Dipexium will be renamed PLx Pharma and will operate under the leadership of...


Microbix Q4 revenue jumps 64% to new record

Sales for Microbix Biosystems (TSX:MBX) in the fourth quarter of fiscal 2016 climbed 64% to $3.5-million, representing the highest quarterly revenue ever achieved by the company, from $2.1-million a year earlier. Net...